Novo Nordisk Announces U.S. Availability Of Awiqli, Its First Once-Weekly Basal Insulin For Adults With Type 2 Diabetes

Novo Nordisk A/S Sponsored ADR Class B

Novo Nordisk A/S Sponsored ADR Class B

NVO

0.00
  • Awiqli® offers adults with type 2 diabetes an alternative to daily basal insulin injections, reducing frequency of these weekly basal injections from seven to one per week1
  • Awiqli® will be available at over 70,000 pharmacies nationwide
  • Affordability programs can be found through NovoCare.com, where eligible patients can pay as little as $35 per month  
This page is machine-translated. Sahm tries to improve but does not guarantee the accuracy and reliability of the translation, and will not be liable for any loss or damage caused by any inaccuracy or omission of the translation. *Disclaimer: The above content only represents the author's personal position and opinion and does not represent any position of Sahm Capital Financial Company and Sahm cannot confirm the authenticity, accuracy, and originality of the above content. Investors should consider the risks of investment products in light of their circumstances before making any investment decisions. When necessary, please consult a professional investment advisor. Sahm does not provide any investment advice, nor does it make any commitments and guarantees.